- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Faricimab, Sham Procedure, Anti-VEGF Therapy
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,036 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 85
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 669
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg, Aflibercept 2.0mg
- Drug
- Lead sponsor
- Arshad Khanani
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Macular Degeneration
- Interventions
- Pegaptanib sodium
- Drug
- Lead sponsor
- Eyetech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Geographic Atrophy, Age Related Macular Degeneration
- Interventions
- IONIS-FB-Lrx, Placebo (sterline saline 0.9%)
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 20 more
- Conditions
- Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related, Maculopathy, Age-Related, Retinal Degeneration, Retinal Neovascularization, Gene Therapy, Therapy, Gene, Eye Diseases
- Interventions
- AAV2-sFLT01
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Worcester, Massachusetts + 1 more
- Conditions
- Age-Related Macular Degeneration, Neovascularization, Choroidal
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 73 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- NeoVista Ophthalmic System
- Device
- Lead sponsor
- NeoVista
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • San Antonio, Texas
- Conditions
- Retinal Hemorrhage, Macular Degeneration
- Interventions
- vitrectomy with subretinal lucentis
- Drug
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
- Interventions
- nGoggle
- Device
- Lead sponsor
- NGoggle
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 200 participants
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Choroidal Neovascularization, Age-Related Maculopathy
- Interventions
- dexamethasone, ranibizumab
- Drug · Biological
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- LMG324, Ranibizumab 0.5 mg, Sham
- Biological
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
- Interventions
- ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
- Drug · Other
- Lead sponsor
- ONL Therapeutics
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 56
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more
- Conditions
- Non-Exudative Age Related Macular Degeneration
- Interventions
- MC-1101, MC-1101 Vehicle
- Drug
- Lead sponsor
- MacuCLEAR, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Murray, Utah
- Conditions
- Geographic Atrophy
- Interventions
- Danicopan, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- Verteporfin, Bevacizumab
- Drug
- Lead sponsor
- Retinal Consultants Medical Group
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Geographic Atrophy
- Interventions
- OpRegen
- Biological
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 15
- States / cities
- Beverly Hills, California • Sacramento, California • San Francisco, California + 12 more
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Not listed
- Lead sponsor
- Michael Abramoff
- Other
- Eligibility
- 45 Years to 120 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Age-Related Macular Degeneration
- Interventions
- FORESEE HOME
- Device
- Lead sponsor
- Notal Vision Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Toms River, New Jersey
- Conditions
- Age-related Macular Degeneration
- Interventions
- Diagnostics
- Diagnostic Test
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neovascular Age-related Macular Degeneration, nAMD
- Interventions
- ABP 938 8 mg, Aflibercept (US) 8 mg
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 55
- States / cities
- Fullerton, California • Long Beach, California • Modesto, California + 50 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- CTx001
- Genetic
- Lead sponsor
- Complement Therapeutics
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
- Interventions
- Metformin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 12
- States / cities
- Davis, California • Palo Alto, California • Sacramento, California + 7 more
- Conditions
- Age-Related (Dry) Macular Degeneration
- Interventions
- AC Tap (anterior chamber paracenthesis)
- Procedure
- Lead sponsor
- ClinOmicsAI
- Network
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Erie, Pennsylvania
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Palmetto Retina Center, LLC
- Other
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Augusta, Georgia • Lincoln, Nebraska • West Columbia, South Carolina + 3 more